75% of Medicare Seniors Face Higher Drug Premiums as Trump Ends Subsidies

For investors, government spending is never just a budget issue. It shapes corporate profits, consumer spending, and entire industries. Healthcare is one of the clearest examples, because a single policy change can redirect billions of dollars between taxpayers, insurers, drugmakers, and beneficiaries.

That is exactly what is happening with Medicare Part D. The Trump administration has decided to end a temporary subsidy program that helped hold prescription drug plan premiums in check, shifting more of those costs back to the market beginning in 2027. The decision may trim federal spending, but millions of Medicare beneficiaries are about to notice the change in their monthly bills.

Ending a $9.8 Billion Stabilization Program

The Centers for Medicare and Medicaid Services (CMS) confirmed on July 28 that it will allow the Medicare Part D Premium Stabilization Demonstration to expire after the 2026 plan year, two years earlier than originally planned. The decision, first reported by The Wall Street Journal, ends a Biden-era program that provided about $3.6 billion to private insurers in 2026 alone to help offset the higher costs created by the redesigned Medicare Part D benefit under the Inflation Reduction Act. Over its two-year life in 2025 and 2026, the demonstration totaled $9.8 billion in federal subsidies.

The mechanics of the program were straightforward. In 2025, CMS paid insurers a $15 monthly subsidy per enrolled member and capped how much any individual plan could raise its premium year over year. For 2026, the Trump administration scaled back the per-member payment to $10 and loosened the cap. According to the federal Medicare Payment Advisory Commission, the subsidy shaved roughly $16 off the average monthly premium in 2026, bringing it down to approximately $36 for the roughly 25 million beneficiaries enrolled in standalone Part D plans.

The Trump administration argues its mission is now complete. After two years operating under the redesigned Part D benefit, CMS says insurers have accumulated enough claims data to price plans without extra taxpayer support. CMS Administrator Dr. Mehmet Oz described the program as a temporary bailout for insurers that distorted pricing rather than allowing the market to set premiums.

^{Sources: Centers for Medicare and Medicaid Services, The Wall Street Journal, Medicare Payment Advisory Commission.}

Higher Premiums Are Coming, But Not Equally

The headline number sounds alarming, yet the details matter. CMS estimates that approximately 25% of beneficiaries will see premiums stay flat or even decline in 2027. About 30% are expected to pay less than $10 more per month. The remaining 45% of enrollees could face increases in the $11 to $20 per month range, depending on their plan and market.

That means roughly three out of every four Medicare Part D participants are expected to pay more than they do today, even if many of those increases remain modest in dollar terms. The Inflation Reduction Act still limits annual increases in the base beneficiary premium to 6% through 2029, and CMS has confirmed the 2027 base premium will be $41.33. Low-cost plan options are expected to remain available in most markets.

One protection that is not changing: the annual out-of-pocket cap on covered drug spending. That limit was set at $2,100 in 2026 and is projected to rise to $2,400 for 2027, a fact the administration has emphasized in response to criticism. The premium increase and the out-of-pocket cap are separate levers, and the latter remains in place regardless of what happens to monthly premiums.

Timing, however, adds political weight to the numbers. CMS is expected to release final 2027 plan details in mid-to-late September. Beneficiaries will then receive their Annual Notice of Change letters from their current plans by the end of September, with open enrollment running from October 15 through December 7, just weeks before the November midterm elections. Older Americans, who vote in higher numbers than almost any other age group, will be reviewing premium increases at precisely the moment candidates are competing hardest for their support.

Why Investors Should Pay Attention

For investors, this story extends well beyond Medicare premiums. The Trump administration has pursued multiple initiatives aimed at lowering prescription drug costs, including expanding Most Favored Nation pricing concepts and continuing Medicare drug price negotiations established under prior law. Ending the premium stabilization program moves in the opposite direction for consumers by asking beneficiaries to absorb more of the actual insurance cost while reducing federal support for insurers.

That creates a distinct set of winners and losers. Federal spending declines by billions of dollars, private insurers lose a subsidy that had supported profitability, and beneficiaries shoulder more of the premium burden. Drug manufacturers remain largely unaffected by this specific policy, because the redesigned Part D benefit and negotiated drug pricing continue separately.

One investor-relevant wildcard is whether rising standalone Part D premiums push beneficiaries toward Medicare Advantage plans, which carried an average drug coverage premium of just $8 per month in 2026 compared to $36 for standalone plans. A meaningful enrollment shift would benefit the insurers with the largest Medicare Advantage books of business and could accelerate a trend that has reshaped the Medicare market for more than a decade.

For investors evaluating healthcare insurers, the 2027 enrollment season, beginning October 15, will provide valuable insight into how aggressively companies price standalone plans without federal assistance and whether beneficiaries respond by migrating to alternative coverage.

Key Takeaway

This is less about a sudden spike in Medicare costs than a shift in who pays the bill. The Biden administration used a $9.8 billion, two-year demonstration program to cushion premium increases while insurers adjusted to the Inflation Reduction Act’s redesigned Part D benefit. The Trump administration, having scaled the program back once already, now believes that transition period is over and that taxpayers should no longer carry the cost.

The numbers suggest most Medicare Part D beneficiaries will pay more in 2027, even if many increases remain below $10 per month. For healthcare investors, the more important question is whether insurers can retain members and protect margins once the federal safety net disappears, and whether the premium gap between standalone plans and Medicare Advantage accelerates enrollment migration. Both answers will become clearer when final 2027 plan pricing arrives this September.

Editor’s note: This update adds the full two-year program cost of $9.8 billion (compared with only the 2026 figure of $3.6 billion cited in the original), the per-member monthly subsidy amounts of $15 in 2025 and $10 in 2026, the MedPAC estimate that the subsidy offset approximately $16 per month in 2026, the confirmed 2027 base beneficiary premium of $41.33 set by CMS, the projected rise in the annual out-of-pocket drug cap from $2,100 to $2,400, specific open enrollment dates of October 15 through December 7, and context on the potential shift of beneficiaries toward Medicare Advantage plans whose drug coverage averaged $8 per month in 2026.

Contact [email protected] for any questions or corrections.